Morgan Stanley Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on Amicus Therapeutics but lowers the price target from $19 to $18.
October 11, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained its Overweight rating on Amicus Therapeutics but has lowered the price target from $19 to $18, indicating a slight decrease in expected stock performance.
The Overweight rating suggests continued confidence in Amicus Therapeutics, but the lowered price target indicates a slight reduction in expected performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100